Cancer is a progressive disease in which a tumor cell temporally develops qualitatively new transformation related phenotypes or a further elaboration of existing transformation associated properties. Subtraction hybridization identi®ed a novel gene associated with transformation progression in mutant adenovirus type 5, H5ts125, transformed rat embryo cells, progression elevated gene-3 (PEG-3). To de®ne the mechanism by which expression of PEG-3 is enhanced as a function of cancer progression a 5'-¯anking promoter region of *2.0-kb, PEG-Prom, was isolated, cloned and characterized. The full-length and various mutated regions of the PEG-Prom were linked to a luciferase reporter construct and evaluated for promoter activity during cancer progression. These assays demonstrate a requirement for AP1 and PEA3 sites adjacent to the TATA box region of PEG-3 in mediating basal promoter activity and the enhanced expression of PEG-3 in progressed H5-ts125-transformed rat embryo cells. An involvement of AP1 and PEA3 in PEG-3 regulation was also con®rmed by electrophoretic mobility shift assays (EMSA) and transfection studies with cJun and PEA3 expression vectors. Our ®ndings document the importance of both AP1 and PEA3 transcription factors in mediating basal and elevated expression of PEG-3 in H5ts125-transformed rat embryo cells displaying an aggressive and progressed cancer phenotype. Oncogene (2000) 19, 3411 ± 3421.
Introduction
The carcinogenic process involves a series of sequential changes in the phenotype of a cell, resulting in new properties or a further elaboration of transformationassociated traits by the evolving tumor cell (Fisher, 1984; Bishop, 1991; Knudson, 1993; Vogelstein and Kinzler, 1993) . Although extensively studied, the precise genetic mechanisms underlying tumor cell progression during the development of most human cancers remain unknown. Experimental evidence indicates that a number of diverse acting genetic elements can contribute to cancer development and transformation progression (Fisher, 1984; Bishop, 1991; Liotta et al., 1991; Knudson, 1993; Levine, 1993; Hartwell and Kastan, 1994; Kang et al., 1998a; Vogelstein and Kinzler, 1993; Su et al., 1997 Su et al., , 1999 . Important target genes involved in these processes include, oncogenes, tumor suppressor genes and genes regulating genomic stability, cancer aggressiveness and angiogenesis (Fisher, 1984; Bishop, 1991; Liotta et al., 1991; Knudson, 1993; Levine, 1993; Hartwell and Kastan, 1994; Kang et al., 1998a; Vogelstein and Kinzler, 1993; Su et al., 1997 Su et al., , 1999 . Recently, several novel genetic elements have been identi®ed that associate with or in speci®c instances directly regulate cancer aggressiveness, i.e., progression elevated (PEGen) and progression suppressed (PSGen) genes (Kang et al., 1998a; Su et al., 1997 Su et al., , 1999 ). The precise mechanism by which these dierent genes orchestrate the complex process of cancer progression represent an important area of investigation with potential for de®ning novel pathways and target molecules that could lead to new diagnostic and therapeutic approaches for cancer.
A useful model for de®ning the genetic and biochemical changes mediating tumor progression is the Ad5/early passage RE cell culture system (Fisher, 1984; Babiss et al., 1985; Duigou et al., 1989 Duigou et al., , 1990 Duigou et al., , 1991 Fisher et al., 1979a,b,c; Reddy et al., 1993; Su et al., 1994 Su et al., , 1997 Kang et al., 1998a) . Transformation of secondary rat embryo (RE) cells by Ad5 is often a sequential process resulting in the acquisition of and further elaboration of speci®c phenotypes by the transformed cell (Fisher et al., 1979a,b,c; Babiss et al., 1985) . Progression in the Ad5-transformation model is characterized by the development of enhanced anchorage-independence and tumorigenic capacity (as indicated by a reduced latency time for tumor formation in nude mice) (Fisher, 1984; Babiss et al., 1985) . The progression phenotype in Ad5-transformed RE cells can be induced by selection for growth in agar or tumor formation in nude mice (Fisher et al., 1979a,b,c; Babiss et al., 1985) , by transfection with oncogenes, such as Ha-ras, v-src, v-raf or the E6/E7 region of human papilloma virus type 18 (Duigou et al., 1989; Reddy et al., 1993) or by transfection with speci®c signal transducing genes, such as protein kinase C (Su et al., 1994) . Progression, induced spontaneously or after gene transfer, is a stable cellular trait that remains undiminished in Ad5-transformed RE cells even after extensive passage (4100) in monolayer culture (Fisher, 1984; Babiss et al., 1985; Reddy et al., 1993) . However, a single-treatment with the demethylating agent 5-azacytidine (AZA) results in a stable reversion in transformation progression in 495% of cellular clones (Fisher, 1984; Babiss et al., 1985; Duigou et al., 1989; Reddy et al., 1993; Su et al., 1994) . The progression phenotype is also suppressed in somatic cell hybrids formed between normal or un-progressed transformed cells and progressed cells (Duigou et al., 1990 (Duigou et al., , 1991 Reddy et al., 1993) . These ®ndings suggest that progression may result from the activation of speci®c progression-promoting (progression elevated) genes or the selective inhibition of progression-suppressing (progression suppressed) genes, or possibly a combination of both processes (Fisher, 1984; Babiss et al., 1985; Su et al., 1997; Kang et al., 1998a) . To identify potential progression inducing genes with elevated expression in progressed versus unprogressed Ad5-transformed cells we are using subtraction hybridization and reciprocal subtraction dierential RNA display (RSDD) approaches (Jiang and Fisher, 1993; Reddy et al., 1993; Su et al., 1997; Kang et al., 1998a) . The subtraction hybridization approach resulted in cloning of PEG-3 which displays elevated expression in progressed cells (spontaneous, oncogene-induced or growth factor-related gene-induced) than in un-progressed cells (parental Ad5-transformed, AZA-suppressed, and suppressed somatic cell hybrids) (Su et al., 1997) . These ®ndings document a direct correlation between expression of PEG-3 and the progression phenotype in this rat embryo model system.
Nuclear run-on assays con®rm a direct correlation between PEG-3 expression and an increase in the rate of RNA transcription of this gene (Su et al., 1997) . To elucidate the mechanism underlying the dierential expression of PEG-3 during transformation progression the 5'-¯anking region of this gene, which contains the promoter (PEG-Prom) has been isolated and characterized. The full-length *2.0 kb PEG-Prom and various mutations (including deletions and point mutations) in the PEGProm were constructed and analysed. The results of this inquiry demonstrate that AP1 and PEA3 transcription factors are the primary determinants of the elevated expression of PEG-3 in progressed Ad5-transformed RE cells. This conclusion is veri®ed by electrophoretic mobility shift assays (EMSA) and transfection studies with c-Jun and PEA3 expression vectors.
Results

Expression of PEG3 directly correlates with transformation progression
To evaluate the relationship between PEG-3 expression and transformation progression we have used a series of rodent cell lines that span the gamut from normal to highly progressed (Fisher et al., 1978; Babiss et al., 1985; Duigou et al., 1989; Reddy et al., 1993; Su et al., 1997 Su et al., , 1999 . A hallmark of the progression phenotype in this rodent model is the ability to grow with enhanced eciency in an anchorage-independent manner and to induce tumors in nude mice with a reduced tumor latency time (18 ± 21 days as opposed to 38 ± 44 days, respectively) (Babiss et al., 1985; Su et al., 1999) . A speci®c H5ts125-transformed secondary Sprague-Dawley RE clone, E11, grows in agar with low eciency (*2 ± 4%) (progression negative), whereas a highly progressed nude mouse tumor-derived E11 subclone, E11-NMT, grows with high eciency in agar (*30 ± 45%) (Figure 1a ). Forced expression of the Ha-ras oncogene in E11 cells, E11-ras R12 as a representative clone, results in acquisition of the progression phenotype as indicated by both anchorage-independent growth ( Figure 1a ) and tumor A B C Figure 1 Anchorage independent growth and PEG-3 mRNA and protein expression in normal, adenovirus-transformed and somatic cell hybrid rodent cells. (a) Anchorage-independent growth assays were determined by plating 5610 3 or 1610 4 cells in 0.4% agar containing medium on top of a 0.8% agar medium containing base layer. After 2 weeks growth, colonies 50.1 mm were enumerated using an inverted microscope. The results are the average of three independent experiments using triplicate samples per experiment+s.d. (b) PEG-3 mRNA levels were determined by electrophoresing 15 mg of total cellular RNA in a 1.2% agarose gel. RNA was transferred to nylon membranes and hybridized with a 32 P-labeled PEG-3 cDNA probe, the blot was stripped and then rehybridized with a 32 P-labeled GAPDH probe. (c) PEG-3 and actin protein levels were determined by Western blotting. Ten mg of protein from each cell type was loaded onto a 10% denatured polyacrylamide gel and electrophoreised for 3 h followed by transfer to a nitrocellulose membrane. PEG-3 protein was detected using Anti-PEG-3 antibody and actin protein was detected by Anti-Actin antibody. Lane designation: 1 E11; 2 E11-NMT; 3 E11-Ha-ras R12; 4 E11-NMT X CREF R1; 5 E11-NMT X CREF R2; 6 E11-NMT X CREF F1; 7 E11-NMT X CREF F2; and 8 CREF latency time in nude mice (Reddy et al., 1993) . Quantifying PEG-3 mRNA levels by Northern hybridization ( Figure 1b ) and PEG-3 protein levels by Western blotting (Figure 1c) indicates a direct correlation between PEG-3 expression, elevated in E11-NMT and E11-ras R12 and reduced in E11, and expression of the progression phenotype (as indicated by anchorage independent growth).
To explore further the relationship between PEG-3 expression and progression the same three parameters as measured for E11, E11-NMT and E11-ras R12 cells were used to compare a series of somatic cell hybrids formed between E11-NMT and CREF cells (Figure 1 ). CREF cells are immortal rat embryo cells that do not form colonies when grown in agar and are devoid of tumorigenic potential when inoculated subcutaneously into athymic nude mice (Fisher et al., 1982; Duigou et al., 1990) (Figure 1a) . Similarly, somatic cell hybrids formed between E11-NMT and CREF cells, that display a¯at morphology such as F1 and F2, also fail to form tumors in nude mice (Duigou et al., 1990) , although they grow with a low eciency in agar similar to E11 cells ( Figure 1a ). In contrast, speci®c E11-NMT6CREF somatic cell hybrids, that display a round morphology such as R1 and R2, grow with high eciency in agar, even exceeding that of E11-NMT ( Figure 1a ) and they rapidly form tumors in nude mice (Duigou et al., 1990) . As observed with E11 cells, the levels of PEG-3 mRNA and protein are reduced in F1 and F2 cells, whereas R1 and R2 display elevated expression of PEG-3 akin to that of E11-NMT and E11-ras R12 cells (Figure 1b,c) . In the case of CREF cells, PEG-3 mRNA is detected at very low levels by Northern blotting (Figure 1b ) and PEG-3 protein is barely detectable by Western blotting (Figure 1c) . These results indicate a direct concordance between PEG-3 expression and the progression phenotype in H5ts125-transformed RE cells.
Isolation of the PEG3 promoter and identification of the transcription start site
Based on the sequence of the PEG-3 cDNA, a genomic walking approach from the 5' region of the PEG-3 cDNA was used to identify a 2.0-kb rat genomic fragment that represents the 5'¯anking region of the PEG-3 gene. The sequence of the putative FL-PEGProm, is shown in Figure 2 . The transcription start site To de®ne the region(s) of the FL-PEG-Prom involved in the dierential expression of the PEG-3 gene during progression of the transformed phenotype in H5ts125-transformed cells, a series of PEG-Prom deletion constructs were engineered and placed in front of the luciferase gene (Figures 5 and 6 ). Deletion of the PEA3 site at position 71645 and the TATA box at position 71072 did not eect PEG promoter activity in either E11 or E11-NMT, suggesting that these regions of the promoter do not contribute to basal or enhanced expression of the PEG-Prom in E11 or E11-NMT cells ( Figure 5 ). A further deletion at position 7270 minimally inhibited promoter activity in E11-NMT cells (*19% reduction versus activity of the FL-PEG-Prom) without signi®cantly altering activity of the PEG-Prom in E11 cells. In contrast, removal of the PEA3 site at 7104 nt with retention of the TATA box at position 724 and the AP1 site at +8 bp resulted in a reduction in basal promoter activity in both E11 and E11-NMT cells. The activity of this mutant PEG-Prom was 15-and fourfold lower, respectively, than the activity of the FL-PEG-Prom in E11-NMT and E11 cells ( Figure 5 ). In eect, this promoter deletion eliminated the enhanced expression of the PEG-Prom in E11-NMT versus E11 cells, indicating that the PEA3 site at 7104 is a primary determinant of the enhanced activity of PEG-3 in progressed H5ts125-transformed RE cells. Internal deletions at position 71167 to 7536 and 71267 to 7536 resulted in similar levels of luciferase activity in E11-NMT and E11 cells as observed with the deletion mutant containing a deletion at position 7270. Internal deletions engineered between 71167 to 7142 and 71590 to 7142 resulted in a further decrease in promoter activity in both E11 and E11-NMT cells, with the most profound eect apparent in E11-NMT cells (*41% reduction in activity in comparison with the FL-PEG-Prom). In contrast, deletion of the promoter regions from 7142, 7536 or 71287 with retention of the remainder of the PEG-Prom completely abolished PEG promoter activity ( Figure 5 ). These results implicate the PEA3 transcription site (at position 7104), the AP1 transcription site (at position +8) and the TATA box (at position 724) as primary determinants of basal PEGProm activity in E11 and E11-NMT cells. + RNAs from E11-NMT or E11 cells and used as a template for the primer extension assay. The conditions used for reverse transcription were as described in Materials and methods. A DNA sequencing reaction, using the same primer and PEG-3 promoter as the template, was electrophoresed in parallel in the same gel with the primer extension reaction Figure 4 Full-length PEG-3 promoter-luciferase activity in normal, adenovirus transformed and somatic cell hybrid rodent cells. Dierent cell types were co-transfected with 5 mg of the FL PEG-Prom and 1 mg of a pSV-b-galactosidase plasmid and luciferase activity was determined as described in Materials and methods 48 h later. The results are standardized by bgalactosidase activity and represent the average of three independent experiments+s.d. Results are expressed as fold activation in comparison with activity in E11, which represents one fold activation. Lane designation: 1 E11; 2 E11-NMT; 3 E11-Ha-ras R12; 4 E11-NMT X CREF R1; 5 E11-NMT X CREF R2; 6 E11-NMT X CREF F1; 7 E11-NMT X CREF F2; and 8 CREF To examine further the role of the PEA3 site at position 7104, the TATA box at position 724 and the AP1 site at position +8 in the regulation of PEG-3 promoter activity in E11 and E11-NMT cells an additional series of mutant PEG-3 promoter luciferase constructs were generated ( Figure 6 ). Mutation in the AP1 site, with retention of the wt PEA3 and TATA sites, resulted in equivalent promoter activity in E11 and E11-NMT cells. This observation emphasizes the importance of the AP1 site at position +8 in the PEG promoter in regulating elevated PEG-3 transcriptional activity in E11-NMT versus E11 cells. An involvement of the PEA3 site at position 7104 in de®ning PEG promoter activity was also demonstrated by analysis of a construct containing a mutated PEA3 site at 7104 with wild-type TATA (at position 724) and AP1 (at position +8) sites ( Figure 6 ). In this mutant, the level of activity of the promoter was at a basal level and the activity was similar in E11 and E11-NMT cells. A similar basal promoter activity was also observed with two additional mutants, one containing mutant AP1 and PEA3 sites and a wild-type TATA box and a A B Figure 5 Mapping the regions of the PEG-3 promoter necessary for basal and elevated PEG-Prom expression in E11 and E11-NMT cells. (a) Schematic representation of deletion mutants of the PEG-Prom. Mutants were constructed as described in Materials and methods. (b) Fold activation of the FL-PEG-Prom (lane 1) and the various PEG-Prom deletion mutants (lanes 2 ± 11) in E11 and E11-NMT cells. Fold activation compares the FL-PEG-Prom and various deletion mutants of PEG-Prom versus the speci®c PEG-Prom deletion construct (deleted at position 740) which contains the TATA box and AP1 element. This deletion construct is given the arbitrary value of one. Promoter-luciferase assays were performed as described in Materials and methods mutant lacking the PEA3 site at position 7104 with wild-type TATA and AP1 sites. In contrast, a mutant lacking the PEA3 site at position 7104 with a mutated TATA site and a wild-type AP1 site at position +8 displayed no promoter activity. These results con®rm that both the AP1 site located at +8 and the PEA3 site at position 7104 are involved in the dierential expression of the PEG-Prom in E11-NMT versus E11 cells. AP1 and PEA3 are major determinants of the dierential expression of the PEG-Prom in E11-NMT versus E11 cells and basal PEG-Prom activity in E11 and E11-NMT cells.
Progressed E11-NMT cells display enhanced nuclear transcription factor binding
Western blotting analysis was performed to determine the levels of AP1/cJun and PEA3 protein in E11 and E11-NMT cells. With both proteins the de novo level of expression was *1.5 ± 2-fold higher in E11-NMT A B Figure 6 Mutation analysis of the PEA3 and AP1 sites and the TATA box in the PEG-Prom. (a) Schematic representation of the speci®c mutations in the PEG-Prom analysed for activity in E11 and E11-NMT cells. Point mutations were made using a sitespeci®c mutagenesis as described in Materials and methods. (b) Fold activation of the various PEG-Prom mutants in E11 and E11-NMT cells. Fold activation compares the PEG-Prom mutant (deleted at position 7118) and additional mutants containing point or deletion mutations eecting the PEA3 and AP1 sites and/or the TATA box region versus the speci®c PEG-Prom deletion construct (deleted at position 740) which contains a wild-type TATA box and AP1 element. This latter deletion construct is given the arbitrary value of 1. Promoter-luciferase assays were performed as described in Materials and methods versus E11 cells (data not shown). EMSA were performed to determine the DNA binding potential of the AP1 and PEA3 proteins and if dierent levels of binding complexes are present in E11-NMT versus E11 cells (Figure 7a,b, respectively) . Using a wild-type AP1 oligonucleotide, the level of binding to AP1 was higher in E11-NMT versus E11 (Figure 7a ). The speci®city of this binding to AP1 was demonstrated by competition with a 10-and a 100-fold molar excess of unlabeled competitor and the absence of a DNA-protein complex when using a mutant AP1 oligonucleotide (Figure 7a ). Direct con®rmation of binding of nuclear extracts to AP1 was provided by supershift assays using cJun (AP1) antibody (Figure 7a ). In contrast, no supershifted DNA-protein complexes were observed when an anti-actin antibody was used in place of the cJun (AP1) antibody. Similar results were obtained when a PEA3 oligonucleotide was used in gel retardation assays (Figure 7b ). Enhanced binding to PEA3 was observed with extracts from E11-NMT versus E11 cells. No binding was observed with a mutated PEA3 oligonucleotide, unlabeled PEA3 competitor eectively inhibited binding to PEA3 and antibodies speci®c for PEA3, but not anti-actin antibodies, resulted in supershifted DNA-protein complexes in the EMSA (Figure 7b ). These experiments demonstrate that E11-NMT cells contain elevated levels of AP1 and PEA3 with the capacity to bind to their respective sites in the promoter of PEG-3.
Ectopic expression of cJun (AP1) and PEA3 in E11 cells independently and cooperatively enhance PEG-Prom activity
The studies described above suggested that AP1 and PEA3 sites in the PEG-Prom were responsible for the dierential activity of this promoter in E11-NMT versus E11 cells. To directly determine if the proteins encoded by these transcription factors can alter the expression of the FL-PEG-Prom in E11 cells transient transfection and promoter-luciferase assays were performed (Figure 8 ). Transfection of E11 cells with an expression vector producing cJun resulted in a dosedependent increase in FL-PEG-Prom activity in E11 cells. The maximum eect obtained was small, equaling only an *1.5-fold increase in cells not expressing the cJun expression plasmid. This stimulatory eect was not evident in cells transfected with a control vector (pcDNA3.1). Moreover, a vector encoding a transactivation domain mutant of the cJun protein, TAM67, resulted in a decrease in PEG-3 promoter activity in E11 cells as would be anticipated with an AP-1 dominant negative mutant protein. Forced expression of PEA3 in E11 cells also resulted in a dose-dependent increase in FL-PEG-Prom activity, again reaching a maximum of *1.5-fold. No enhancement in promoter activity was observed in E11 cells transfected with the control pRC/RSV vector. When E11 cells were cotransfected with a combination of expression vectors producing cJun and PEA3, FL-PEG-Prom activity was comparable to that observed in E11-NMT cells. This eect was not apparent when the combination of control vectors were transfected into E11 cells ( Figure  8 ). These results provide support for the hypothesis that the dierential expression of the PEG-Prom in E11-NMT versus E11 cells is a consequence of elevated expression of cJun (AP1) and PEA3 transcription factors in the progressed E11-NMT cells.
Discussion
Acquisition of enhanced expression of the transformed phenotype, i.e., transformation progression, represents a critical component in the cancer paradigm. A novel cDNA, PEG-3, that displays dierential expression as a function of progression of the transformed phenotype, oncogenic transformation and DNA damage in rodent cells was identi®ed by subtraction hybridization (Su et al., 1997) . Recent studies document that PEG-3 is causally related to cancer progression, since ectopic expression of this gene in transformed rodent or human tumor cells results in an aggressive tumor phenotype when cells are injected subcutaneously into athymic nude mice (Su et al., 1999) . These observations suggest that PEG-3 is an important contributor to transformation progression. To de®ne the mechanism mediating dierential expression of PEG-3 in progressed (E11-NMT) versus unprogressed (E11) Ad5-transformed rat embryo cells the promoter region of this gene was identi®ed, isolated and examined. By using promoter analyses, EMSA and transient transfection assays we presently demonstrate that a combination of the AP1 and PEA3 transcription factor sites in the PEG-Prom adjacent to the TATA region contribute to basal and enhanced promoter activity in H5ts125-transformed RE cells.
Promoter deletion analysis indicates that a region of the PEG-Prom containing 7270/+194 of the PEG-3 gene is essential for PEG-3 transcriptional activity in E11 and E11-NMT cells (Figures 5 and 6) . Moreover, this region of the PEG-Prom is also responsible for the dierential promoter activity of the PEG-Prom in E11-NMT versus E11 cells. Sequence analysis indicates that this part of the PEG-Prom contains AP1 (+8), TATA (724) and PEA3 (7104) elements (Figure 2) . A mutation of the AP1 site at +8, while retaining a wild-type TATA and PEA3 sequence, reduces the activity of the PEG-Prom deletion construct (7270/+194) in E11-NMT to that of E11 cells (Figure 6b ). This ®nding suggests that the AP1 site at +8 is a primary determinant of the dierential expression of the PEG-Prom in E11-NMT versus E11 cells. The importance of the TATA and PEA3 sites in PEG-Prom activity is also documented using additional mutants (Figure 6b) . A mutation in the PEA3 site (7104) in the presence of wild-type TATA (724) and AP1 (+8) sites reduces promoter activity in E11 and E11-NMT and eectively eliminates the enhanced activity of the PEG-Prom in E11-NMT cells. Similar levels of reduced PEG-Prom activity are apparent in both E11 and E11-NMT cells when the AP1 (+8) site is mutated singly or in combination with a mutated PEA3 (+8) site. In these contexts, altering the AP1 (+8) and PEA3 (7104) sites, singly or in combination, eects both basal and enhanced PEG-Prom activity. Moreover, a mutation in the TATA region (724), even in the presence of a wild-type AP1 (+8) site, results in an extinction of promoter activity. These results demonstrate that both AP1 and PEA3 sites adjacent to an intact TATA region within the PEG-Prom contribute to both basal promoter activity in E11 and E11-NMT cells and elevated promoter activity in E11-NMT cells.
A functional interaction between the AP1 and PEA3 sites and binding of nuclear proteins in the FL-PEG-Prom was strengthened by EMSA using appropriate oligonucleotide probes and monoclonal antibodies (Figure 7) . EMSA using nuclear extracts from E11 and E11-NMT cells resulted in slowermigrating DNA-protein complexes when incubated with AP1 or PEA3 oligonucleotides (Figure 7a,b) . The amount of these complexes were reduced or eliminated when a 10-or 100-fold molar excess, respectively, of unlabeled oligonucleotides were incorporated in the assay. No DNA-protein complexes were observed when a mutated AP1 or PEA3 oligonucleotide was used in the binding assay. The speci®city of the nuclear protein binding was demonstrated using antibody speci®c for cJun (AP1) or PEA3 in the EMSA. In these experiments supershifted slow-migrating DNA-protein complexes were apparent resulting from antibody interactions with the DNAprotein complexes. The amount of AP1 and PEA3 complexes present in E11-NMT cells exceed that found in E11 cells (Figure 7a,b) . Moreover, a small but signi®cant increase (*1.5 ± 2-fold) in the levels of AP1/cJun and PEA3 protein was also detected by Western blotting in E11-NMT versus E11 cells (unpublished data). The functional signi®cance of the elevated AP1 and PEA3 proteins in E11-NMT versus E11 cells in regulating elevated PEG-3 promoter activity in the progressed cells was documented by transient transfection of cJun and PEA3 expression vectors (Figure 8) . These experiments demonstrated that transient ectopic cJun (AP1) and PEA3 expression can individually elevate PEG-Prom activity in E11 cells and the combination of both transcription factors results in an additive eect culminating in a similar PEG-Prom activity as observed in E11-NMT cells (Figure 8 ). Additional support for a role of AP1 in regulating PEG-3 promoter activity was demonstrated using a dominant negative transactivation domain mutant of cJun, TAM67, which inhibited PEG-3 promoter activity in E11 cells in a dosedependent manner (Figure 8 ). Based on increased binding activity in EMSA, increased levels of protein in Western blots and cotransfection assays there appears to be a strong correlation between PEG-3 expression and AP1/PEA3 activity.
AP1 transcription factors are immediate early response genes that regulate expression of a subset of target gene promoters containing de®ned sequence motifs (TPA-response elements, TRE) (Angel and Karin, 1991) . The AP1 complex comprises a heterodimer of a member of the Fos family and a member of the Jun family or homodimers of members of the Jun family (Angel and Karin, 1991 , Karin et al., 1997 . AP1 contributes to many important and diverse biological processes including cell proliferation, transformation, onocogenesis, dierentiation and apoptosis (Angel and Karin, 1991; Karin et al., 1997; Olive et al., 1997; Kang et al., 1998b) . The transcription factor PEA3 a member of the ets gene family is also a major contributor to cell transformation and oncogenesis (Brown and McKnight, 1992) . PEA3 proteins interact with an *10 base pair DNA sequence in the promoters of target genes resulting in regulation of transcription (Macleod et al., 1992; Seth et al., 1992; Wasylyk et al., 1993) . Putative candidate PEA3 target genes include proteinases required for degradation of the extracellular matrix, including the serine urokinasetype plasminogen activator (Nerlov et al., 1992) and matrix metalloproteinases gelatinase B, interstitial collagenase, stromelysin-3 and matrilysin (Matrisian and Bowden, 1990; Matrisian, 1994; Higashino et al., 1995) , which represent important factors contributing to cancer metastasis (Liotta et al., 1991; Kohn and Liotta, 1995) . Many of these extracellular matrix degrading genes also contain AP1 sites in their promoters (Angel and Karin, 1991; Karin et al., 1997) . Cooperation between AP1 and PEA3 sites in regulating several cellular promoters have been documented. These include, serum growth factor response of the tissue inhibitor of metalloproteinases-1 (TIMP-1) gene (Edwards et al., 1992) and 12-0-tetradecanoylphorbol 13-acetate (TPA), ®broblast growth factor-2 (FGF-2) and macrophage colony-stimulating factor induction of the urokinase-type plasminogen activator gene (Nerlov et al., 1992; Stacey et al., 1995; De Cesare et al., 1996; D'Orazio et al., 1997) . Moreover, PEA3 and AP1 elements are also present in the promoters of the stromelysin and collagenase genes (Gutman and Wasylyk, 1990; Sirum-Conolly and Brinckerho, 1991) and these elements provide targets for transcriptional activation by speci®c transforming oncogenes (Wasylyk et al., 1989 (Wasylyk et al., , 1993 . In these contexts, the increased AP1 and PEA3 activity in E11-NMT cells versus E11 can result in elevated PEG-Prom activity and thereby increased PEG-3 protein which can directly contribute to cancer aggressiveness, resulting in enhanced tumor growth in vivo in nude mice, in the progressed tumor cells. The increased activity of AP1 and PEA3 in E11-NMT cells will also likely activate additional downstream genes that can facilitate the cancer phenotype.
The mechanism by which PEG-3 facilitates expression of the transformed phenotype is not currently known. Forced expression of the rat PEG-3 gene in both rodent and human cancer cells results in an increase in anchorage independent growth and an augmentation in oncogenic potential (Su et al., 1997 (Su et al., , 1999 . One putative target for PEG-3 is the angiogenesis-inducing molecule, vascular endothelial growth factor (VEGF) (Su et al., 1999) . Stable elevated expression of PEG-3 results in increased VEGF RNA transcription, steady-state mRNA and secreted protein in E11 cells. Moreover, a VEGF-luciferase reporter construct displays enhanced activity in cells expressing PEG-3. A functional role for PEG-3 in regulating VEGF expression is demonstrated further by inhibiting PEG-3 expression in E11-NMT cells using a stable antisense PEG-3 expression vector which results in a decrease in VEGF mRNA and secreted protein. The requirement for PEG-3 protein in inducing VEGF expression was demonstrated by simultaneous treatment of PEG-3 transfected cells with the protein synthesis inhibitor cycloheximide (Su et al., 1999) . In this experiment, the transfected PEG-3 gene was expressed as PEG-3 mRNA, whereas VEGF mRNA was only present in cells not exposed to cycloheximide. Although it is not presently known if PEG-3 binds directly to the VEGF promoter or activation of VEGF transcription occurs by means of additional molecules, these studies suggest an association between PEG-3 expression, induction of angiogenesis and facilitation of expression of the cancer state.
Further studies are necessary to identify and characterize the repertoire of down-stream genes modulated as a consequence of PEG-3 expression and to determine their roles in facilitating cancer aggressiveness and angiogenesis. These investigations are important and oer potential for de®ning the genetic elements which are critical determinants of the cancer phenotype. With this information it will be possible to demarcate potential targets and de®ne appropriate reagents, such as antisense or small molecule antagonists, for inhibiting or preventing cancer development and progression.
Materials and methods
Cell cultures
E11 is a single cell clone of H5ts125-transformed SpragueDawley secondary RE cells (Fisher et al., 1978) . E11-NMT is a subclone of E11 cells derived from a nude mouse tumor induced by the E11 cell line (Babiss et al., 1985) . R12 is a Haras oncogene transformed E11 clone (Duigou et al., 1989) . F1 and F2 are suppressed somatic cell hybrids with a¯at morphology that were formed between E11-NMT and CREF cells (Duigou et al., 1990) . R1 and R2 are progressed somatic cell hybrids with a round morphology that were created by fusing E11-NMT and CREF cells (Duigou et al., 1990) . CREF is a speci®c immortal non-transformed and nontumorigenic clone of Fischer rat embryo ®broblast cells (Fisher et al., 1982) . All cultures were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 5% FBS (DMEM-5) at 378C in a humidi®ed 5% CO 2 95% air incubator.
Northern and Western blotting assays
Total cellular RNA was isolated by the guanidinium/phenol extraction method and Northern blotting was performed as described (Su et al., 1994 (Su et al., , 1997 . Fifteen mg of RNA were denatured and electrophoresed in 1.2% agarose gels with 3% formaldehyde, transferred to nylon membranes and hybridized sequentially with 32 P-labeled cDNA probes as described previously (Su et al., 1994 (Su et al., , 1997 . Following hybridization, the ®lters were washed and exposed for autoradiography. Western blotting analyses (Su et al., 1995) detected cJun (AP1), PEA3, PEG-3 and actin proteins. Five million cells were seeded into 100-mm plates and incubated for 24 h at 378C. The medium (DMEM-5) was removed, the cells were washed three times with cold PBS and then lysed in RIPC buer (0.5 M NaCl, 0.5% NP40, 20 mM TrisHCl, pH 8, 1 mM PMSF). The protein levels were determined using an ECL kit (Amersham) and the respective antibodies (Santa Cruz). Cell lysates were also analysed using rabbit anti-PEG-3 polyclonal antibodies against C-terminal peptides.
Isolation and analysis of the PEG3 promoter
Based on the 5' sequence of the PEG-3 cDNA, two nested primers with the sequences GATCTAGGGTGTTGTGA-GAGGATCGGAG and TCGGTTTGCCAAAAGCGATC-GTGGG were used with a Genome Walker Kit (Clontech) to obtain a genomic sequence containing the putative promoter of PEG-3. Three DNA fragments of 2.0-, 1.6-and 1.0-kb, respectively, with identical and overlapping nucleotide sequences were obtained using this approach. The 2.0-kb PEG-3 fragment (designated FL-PEG-Prom) was cloned into the pGL3-basic Vector (Promega) for promoter activity analysis. 5'-Deletion mutations in the FL-PEG-Prom were made with exonuclease III digestion using the Erase-A-Base System (Promega). 3'-Deletion mutations of the FL-PEGProm were made by digestion with BstEII/XhoI, SacII/XhoI and NdeI/XhoI, respectively. BstEII, SacII and NdeI are single ± cut restriction endonucleases recognizing DNA sequences in the FL-PEG-Prom, XhoI restriction site is located in the MCS of pGL3 vector near the 3' end of the FL-PEGProm. The internal deletions were performed by digesting the FL-PEG-Prom with NdeI/SacII, NdeI/BstEII, StuI/BstEII and BstXI, respectively. Mutations in the AP1-binding site, PEA3-binding site, and TATA box were made using a sitespeci®c mutagenesis method with the Altered Sites II In Vitro Mutagenesis System (Promega). The PEG-Prom deletion mutants were cloned into the pGL3-basic Luciferase Reporter Vector (Promega). To evaluate the activity of the various PEG-Prom-luciferase constructs, cells were seeded at 2610 5 /35-mm tissue culture plate and *24 h later transfected with 5 mg of the various PEG-Prom-luciferase constructs plus 1 mg of SV40-b-gal Vector (Promega) mixed with 10 ml of Lipofectamine Reagent (Gibco) in 200 ml of serum-free media. After 20 min at RT, 800 ml of serum-free media were added resulting in a ®nal volume of 1 ml. The transfection mixture was removed after 14 h and the cells were washed three times with serum-free media and incubated at 378C for an additional 48 h in complete growth media. Cells were harvested and lysed to make extracts (Gopalkrishnan et al., 1999) utilized in b-gal and Luciferase reporter assays. Luminometric determinations of Luciferase and b-gal activity was performed using commercial kits (Promega and Tropix, respectively). For Luciferase assays, 10 ml of cell lysate were mixed with 40 ml of Luciferase Assay substrate (Promega). For b-gal assays, 10 ml of the cell lysate were mixed with 100 ml of diluted Galecton-Plus with 150 ml of Accelerator (Tropix). Promoter analysis data were collected a minimum of three times using triplicate samples for each experimental point and the data was standardized with the b-gal data.
Primer extension of E11 and E11-NMT mRNA
A primer with the sequence 5'-GGCAAAGGGATGCG-GAGTCGCGCGGGTCTCGCATG-3' complementary to the 5' UTR sequence of the PEG-3 cDNA was annealed to 4 mg of PolyA + RNAs from E-11 or E11-NMT cells, which were used as template for primer extension with reverse transcriptase. In brief, 20 pmol of dephosphorylated oligo-DNA was end-labeled with g-32 P-ATP (Amersham) and T4 polynucleotide kinase. The labeled oligonucleotides (56 10 5 c.p.m.) were incubated with 4 mg of polyA + RNA and the precipitate was resuspended in DEPC-treated H 2 0. The reverse transcription reaction contained 200 u/ml of Superscript Reverse Transcriptase II (Gibco), 50 mM of Tris-HCl (pH 8.3), 40 mM KCl, 6 mM MgCl 2 , 1 mM DTT, 1 mM dNTP, and 0.1 mg/ml BSA. The mixture was incubated at 428C for 1 h followed by the addition of 1 ml of 0.5 M EDTA (pH 8) to stop the reaction. After DNase-free RNase treatment, the reaction mixture was loaded onto a 5% urea polyacrylamide sequencing gel in parallel with a DNA sequencing reaction using the same primer and template.
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared from 2 ± 5610 8 cells as described by Dignam et al. (1983) . The sequence of probes were as follows: wild-type AP1, 5'-CGCAGATTGACTCAG-TTCGC-3'/5'-GCGTCTAACTGAGTCAAGCG-3'; mutant AP1, 5'-CGCAGATAAACTACGTTCGC-3'/5'-GCGTCTA-TTTGATGCAAGCG-3'; wild-type PEA3, 5'-GTGTTG-TTTTCCTCTCTCCA-3'/5'-CACAACAAAAGGAGAGAG-GT-3'; and mutant PEA3, 5'-GTGTTGTTCCCATCTCTC-CA-3'/5'-CACAACA AGGGTAGAGAGGT-3'. The doublestranded oligonucleotides were labeled with g-32 P-ATP (Amersham) and T4 polynucleotide kinase. The labeled probes were then incubated with nuclear extract at RT for 30 min. The reaction mixture consisted of 32 P-labeled deoxyoligonucleotides (45000 c.p.m.), 2 mg of poly(dl-dc) and 10 mg of nuclear protein extract with 10 mM HEPES (pH 7.5), 50 mM KCl, 5 mM MgCl 2 , 0.5 mM EDTA, 1 mM DTT and 12.5% glycerol. After incubation for 30 min at RT, the reaction mixtures were electrophoresed on a 5% polyacrylamide gel with 0.56TBE (160 V for 3 h). The gel was dried and autoradiographed. Nuclear extracts were also incubated with a 10-or 100-fold molar excess of cold competitor oligonucleotide or cJun (AP1), PEA3 or actin antibody (1 or 5 mg) together with the 32 P-labeled probe.
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